GERN Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Geron Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.87 |
52 Week High | US$5.34 |
52 Week Low | US$1.64 |
Beta | 0.42 |
1 Month Change | 27.82% |
3 Month Change | 53.39% |
1 Year Change | 62.33% |
3 Year Change | 166.12% |
5 Year Change | 229.05% |
Change since IPO | -37.16% |
Recent News & Updates
Geron: Innovative Rytelo Enters A Challenging MDS Market
Jun 08Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All
May 03Recent updates
Geron: Innovative Rytelo Enters A Challenging MDS Market
Jun 08Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All
May 03Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
Mar 15Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Mar 05Is Geron (NASDAQ:GERN) A Risky Investment?
Aug 25Is Geron (NASDAQ:GERN) Using Debt Sensibly?
May 12An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued
Dec 20Geron: A Major Catalyst For Shareholders Arrives In January - At Last
Sep 16Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?
Sep 14Geron rises on narrower-than-expected Q2 loss
Aug 12Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt
Aug 05Geron: Waiting For Godot
Jul 15Geron: TLR Is 10 Months Away
May 03Shareholder Returns
GERN | US Biotechs | US Market | |
---|---|---|---|
7D | 6.1% | 0.1% | 1.2% |
1Y | 62.3% | 7.1% | 20.8% |
Return vs Industry: GERN exceeded the US Biotechs industry which returned 6.7% over the past year.
Return vs Market: GERN exceeded the US Market which returned 20.6% over the past year.
Price Volatility
GERN volatility | |
---|---|
GERN Average Weekly Movement | 9.7% |
Biotechs Industry Average Movement | 10.3% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.4% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GERN's share price has been volatile over the past 3 months.
Volatility Over Time: GERN's weekly volatility has decreased from 16% to 10% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 141 | Chip Scarlett | www.geron.com |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
GERN fundamental statistics | |
---|---|
Market cap | US$2.89b |
Earnings (TTM) | -US$201.39m |
Revenue (TTM) | US$520.00k |
5,555x
P/S Ratio-14.3x
P/E RatioIs GERN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GERN income statement (TTM) | |
---|---|
Revenue | US$520.00k |
Cost of Revenue | US$125.89m |
Gross Profit | -US$125.37m |
Other Expenses | US$76.02m |
Earnings | -US$201.39m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.34 |
Gross Margin | -24,110.38% |
Net Profit Margin | -38,729.81% |
Debt/Equity Ratio | 24.0% |
How did GERN perform over the long term?
See historical performance and comparison